# MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8510-002)

> **NCT05700734** · PHASE1 · WITHDRAWN · sponsor: **Merck Sharp & Dohme LLC**

## Conditions studied

- HIV-1
- Human Immunodeficiency Virus 1
- Immunodeficiency Virus Type 1, Human
- Human Immunodeficiency Virus Type 1

## Interventions

- **DRUG:** MK-8510

## Key facts

- **NCT ID:** NCT05700734
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-04-17
- **Primary completion:** 2024-02-14
- **Final completion:** 2024-02-14
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business Reasons
- **Last updated:** 2023-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05700734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05700734, "MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8510-002)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05700734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*